Ninety-nine patients with confirmed breast cancer were reviewed to identify patients who had two confirmed malignant lesions of identical pathology (Group-1, N=17), and patients who had one malignant lesion and the second benign lesion (Group-2, N=8). Contrast enhancement kinetics from every lesion was measured and analyzed using three different models to obtain fitting parameters related to up-slope, enhancement amplitude, and washout, including Model-1: modified Tofts model (v p , K trans , k ep ), Model-2: standard Tofts model (K trans , k ep ), and Model-3: a 3-parameter heuristic model (T c , A, C). By analyzing lesions from same patients, the differences in whole body hemodynamics thus the blood kinetics could be controlled. Two questions were addressed in this study: i) What is the association between pharmacokinetic parameters analyzed from multiple cancers of identical pathology in same patients?; and ii) What is the difference between secondary malignant lesions and secondary benign lesions with reference to the primary cancer? All three models could fit the enhancement kinetics satisfactorily. Regardless of the analysis model the parameter obtained from the primary cancer and the secondary cancer showed significant correlations.
Introduction
Lesion size and presence of multifocality or multicentricity are two essential factors for planning breast-conservation surgery. Compared to conventional examinations (clinical, mammography, and ultrasound) , MRI has been proven to be the most sensitive imaging modality in delineating tumor extent (1-3) and detecting multifocal or multicentric diseases (4-5). Many studies have indicated that preoperative MRI is useful in local staging for surgical planning (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , especially for patients with lobular cancer (11) (12) (13) (14) . Additional MRI findings may suggest a wider excision or a change from lumpectomy to mastectomy, and it has been shown to impact positively in 15-30% of cases (4, 5, 9, 11) . A recent study indicated that preoperative MRI may also have positive influence on the recurrence rate, presumably due to a better staging and surgery (15) . However, the incidental findings also lead to unnecessary biopsy or overtreatment (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . The value of MRI in evaluation of contralateral breast or in patients without known malignancy is still questionable (16) (17) (18) (19) . A better characterization of the enhancing lesions noted on MRI is important to avoid unnecessary biopsy or overtreatment, especially when more and more preoperative MRI studies are performed.
High resolution anatomic MRI and dynamic contrast enhanced MRI has evolved into a standard approach for detection and diagnosis of breast lesions (20) (21) . In malignant lesions the enhancement kinetics commonly shows rapid up-slope followed by wash-out, presumably due to higher vascular supply and higher vascular permeability. In contrary, due to lower angiogenesis the benign lesions may show slower up-slope followed by a continuous enhancing or a plateau pattern without wash-out. However, how the contrast enhancement kinetics can be best interpreted is not clear (22) . In clinical settings, the reading is often based on percentage enhancement and wash-out, as used in CADstream™ (Confirma Inc., Kirkland, WA). However, quantitative analysis is needed to correlate the data with other measures related to angiogenesis, e.g. microvessel density and VEGF (23-28). The 2-compartmental model is commonly used to describe the transport of contrast medium in the tissue vascular and interstitial spaces as a function of time, which enables the determination of transport rates between the vascular and extravascular compartments (29). A comprehensive paper was published by Tofts et al., which reported a consensus model with unified terminology, agreed by several research groups working on MRI pharmacokinetic model analysis (30) . One remaining question is whether the vascular component should be included or ignored.
In addition to angiogenesis in the lesion, the contrast enhancement kinetics is also dependent on the hemodynamics of the body. Patients may have different blood circulation leading to different arrival of contrast medium to the breast (affecting up-slope), and they may have different renal function resulting in different decay of contrast medium in the blood kinetics (affecting decay rate). The blood kinetics will affect the obtained fitting parameters (31).
Unfortunately it is very difficult to measure the blood kinetics accurately for each patient. A T1 measurement technique with a high temporal resolution was required to measure the arterial input function (32), and since it would be at the expense of a lower spatial resolution or a limited coverage region, it was not practical in a clinical setting.
In this work instead of measuring the individual blood hemodynamics, it was controlled by studying multiple lesions in the same patient, to reveal different MRI characteristics among multiple lesions. We aimed to address two questions: I) What is the association between fitting parameters analyzed from multiple cancers of identical pathology in same patients? Patients who had a primary cancer and a secondary cancer in the same breast (Group-1) were analyzed to address this question. II) What is the difference between secondary malignant lesions and secondary benign lesions with reference to the primary cancer? Patients who had a primary cancer and a secondary benign lesion (Group-2) were compared to Group-1 patients to address this question. The enhancement kinetics measured from each lesion was analyzed using three different models. Model-1: modified Tofts model, the 2-compartmental pharmacokinetic model with the vascular component, Model-2: standard Tofts model, the 2-compartmental pharmacokinetic model without the vascular component, and Model-3: the 3-parameter heuristic model based on the shape of the curve. The performance of each fitting parameter obtained using these three different models in addressing the two proposed questions was assessed.
Materials and Methods

Subjects
All consecutive breast MRI studies conducted between Jan. 2001 to Sept. 2003 at out institute were reviewed. The study was carried out prospectively. Ninety-nine cases with pathology confirmed cancer were available for this study. Among them, two groups of patients who fit the following criteria were selected for analysis. Group-1: patients with histological confirmed multiple malignant lesions in the same breast, which were greater than 6 mm each and could be distinctly identified on MRI. Group-2: patients with one malignant lesion and one benign lesion (in the same or contralateral breast). For group-1, 15 patients with two malignant lesions of identical pathological nature, and two patients with three identical malignant lesions were found. Among these 17 cases, 12 were invasive ductal carcinoma, three were invasive lobular carcinoma and two were mixed ductal and lobular types. Eight patients (one common patient as in Group-1) with malignant lesions and one histological-proven benign lesion were selected for comparison. Among these eight cases, malignant lesions included six ductal, one lobular, one tubular, and the benign lesions included two atypical ductal hyperplasia, two fibrocystic changes, one fibroadenoma, one papilloma, one lobular hyperplasia, and one sclerosing adenosis. The study was approved by the local institutional review board. All subjects gave informed consent before the MRI study was performed.
MRI Study and Analysis of Contrast Enhancement Kinetics
The MRI study was performed using a 1.5 T Phillips Eclipse MR scanner. After the localizer scan, sagittal view T1-weighted pre-contrast images were acquired from the breast of concern, using a spin echo pulse sequence with TR= 1000 ms, TE=12 ms, FOV= 20 cm, matrix size=256×256, and 34 slices with 3 mm thickness. Following this, a 3D SPGR (RF-FAST) pulse sequence with 16 frames (repetitions) was prescribed for dynamic imaging. Thirty-two axial slices with 4 mm thickness were used to cover bilateral breasts. The imaging parameters were TR= 8.1 ms, TE= 4.0 ms, flip angle=20°, matrix size= 256×128, FOV varying between 32 and 38 cm. The scan time was 39 sec per acquisition. The sequence was repeated 16 times for dynamic acquisitions, 4 pre-contrast, and 12 post-contrast sets. The contrast agent (Omniscan®, 1 cc/10 lbs body weight) was manually injected at the beginning of the 5th acquisition, and was timed to finish in 12 seconds to make the bolus length consistent for all patients. Immediately following the contrast, 10 cc saline was used to flush in all contrast medium. Then the post-contrast sagittal T1-weighted images were acquired. A relatively long injection time was chosen to ensure that the maximum enhancement would not occur before the first post-contrast acquisition was completed.
For analysis, first the color-coded enhancement maps at 1 min post injection were generated, by subtracting the precontrast images (averaging over the first 4 pre-contrast frames) from the post-contrast images taken at the 6th frame (See Figs. 1-4) . The dark reddish color showed the strongest enhancement, then in order orange, yellow, green, and the dark blue showed the lowest enhancement. A default range was first used, then based on the outcome the value was adjusted to best demonstrate the lesion boundary. The ROI was manually placed on the strongly enhanced regions based on the color enhancement maps. Then the signal intensity time courses measured from adjacent slices containing the same lesion, which had similar magnitudes and shapes, were averaged to obtain a final signal intensity time course for each lesion. The post-contrast signal enhancement (postcontrast signal intensity subtracting baseline signal intensity) was divided by the baseline signal intensity to calculate the signal enhancement percentage SE(t), shown in Eq. [1]. The lesions in different regions of the coil might have different intensities due to coil sensitivity inhomogeneity, and normalizing to the baseline intensity could correct for this factor to some extent. The obtained percent enhancement was assumed to be proportional to the total contrast concentration in tissue C t , and was fitted using three different models to obtain the fitting parameters as described next.
Pharmacokinetic Models
Three different models were used to fit the enhancement kinetic time course measured from each lesion, Model-1: modified Tofts model (the 2-compartmental pharmacokinetic model with the vascular component), Model-2: standard Tofts model (the 2-compartmental pharmacokinetic model without the vascular component), and Model-3: the 3-parameter heuristic model (direct fitting based on the shape of the curve). In the consensus paper published by Tofts et al. (30) , the detailed model, the limitations under different conditions, and the association of the fitting parameters with the true physiological parameters, have been discussed thoroughly. Regardless of physiological conditions, the transport between the vascular compartment (plasma) and the extravascular compartment can be expressed as Eq. [2] .
where C e is the concentration of the contrast medium in the extravascular extracellular space (EES), C p is the concentration of the contrast medium in the plasma, and v e is the fractional contrast medium distribution volume in the extravascular extracellular space. The total concentration C t can include both the vascular component and the extravascular component (Model-1, modified Tofts model), as in Eq. [3] where v p is the fractional plasma volume, or ignore the vascular component and only include the extravascular component (Model-2, standard Tofts model), as in Eq. [4].
[3]
The detailed fitting procedures including all mathematical formulas had been described in one previous publication (33). In that work the transport equation was expressed as where K 1 was K trans and K 2 was k ep in the unified Tofts model, and the tissue concentration included both the vascular and the extravascular components as in Eq. [3] . Therefore, that model was identical as the Model-1 in the current study. The concentration of contrast medium in the plasma C p was assumed to follow a linear increase phase after injection (t=0 to t0, t0= 0.75 min) to the maximum value A 0 , then follow a bi-exponential decay with two rate constants 1.109/min (67%) and 0.046/min (33%). The biexponential decay rate constants were obtained from Ref.
(32). The parameter t0 (= 0.75 min) was determined based on the fitting quality. It yielded a satisfactory fitting for all cases. The percentage signal enhancement SE(t) was assumed to be linearly proportional to the contrast medium concentration in the tissue C t , and was directly fitted using the same mathematical formula described in Ref. (33) Figures 1-4 (b). There were three fitting parameters for Model-1, and the fitting always converged to give a satisfactory fitting quality.
The fitting for Model-2 was also based on the same 2-compartmental pharmacokinetic model but ignoring the vascu- The measured percentage enhancement kinetics measured from the lesion shown by blue symbol, and the best fitting curves using Models-1, 2, and 3 shown by red curves, from left to right respectively. All three models show satisfactory fitting. In Model-1, the respective vascular component (light blue curve) and extravascular component (green curve) are shown. The percentage enhancement kinetics and the best fitting curves using Models-1, 2, and 3 are shown from left to right. Models-1 and 3 yield satisfactory fitting, and Model-2 overestimates the decay rate, thus shows a less optimal fitting quality. Instead of setting t0=0.75 min, t0=0.5 min gave a better fitting quality for most cases. There were only two parameters for Model-2, and in some cases the fitting would not converge, or it would yield an unsatisfactory fitting quality. In those cases, t0 was changed to 0.35 or 0.25 min to achieve a satisfactory fitting. Once the value was determined, the same t0 was used in fitting primary and secondary lesions in the same patient. Another option was to fit t0 as well, but it might yield different t0 values for multiple lesions in the same patient, which violated the assumption of same blood kinetics. When t0 was adjusted, K trans was slightly affected (less than 5% difference), and very minimal change for k ep (less than 1%).
In addition to the 2-compartmental pharmacokinetic model which could be used to relate the fitting parameters to physiological parameters, we also used a 3-parameter heuristic model to fit the enhancement time course based on the curve shape. Most enhancement kinetic curves showed an exponential increasing phase followed by a linear decay, which could be modeled by Eq. 
SE(t) =
A [1 -exp(-t/T c )] -Ct [5]
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Figure 7: The correlation between the fitting parameter A (a), T c (b), and C (c) analyzed from primary and secondary lesions using Model-3 (the 3-parameter Heuristic model), blue symbols for Group-1 and red symbols for Group-2. T c and C show significant differences, but not A.
Figure 6:
The correlation between the fitting parameter K trans (a), and k ep (b) analyzed from primary and secondary lesions using Model-2 (the Tofts model without vascular component), blue symbols for Group-1 and red symbols for Group-2. K trans does not yield significant differences, but k ep is significant. 
Pathological Examination
The patients received mastectomy or lumpectomy after the MRI study. The specimens were oriented, and different color ink (Davidson Marking System) was applied to designate each surgical margin. For mastectomy specimen, multiple sagittal slices at 0.5 to 1 cm intervals were made, usually from medial to lateral. Tissue sections were fixed in 10% neutral buffered formalin, processed for histology, and stained with hematoxylin and eosin (H&E). The specimens were examined by an experienced pathologist (PMC) and an attempt was made to identify each lesion noted on MRI, when possible. A representative section of each tumor was reviewed to determine the histological type. The cases with multi-focal or multicentric malignant tumors in the same breast, which had the same pathological feature, were included in this study. For cases with malignant and benign lesions, they might be in different breasts.
Statistical Analysis
Two tests were performed. The first test was to investigate the association between the fitting parameters measured from multiple malignant lesions in same breast of same patient. There were a total of 8 parameters: Model-1: v p , K trans , k ep ; Model-2: K trans , K ep ; and Model-3: A, T c , C. Since the lesions had the same pathological feature, and they were from the same breast in the same patient (so that the blood kinetics was identical), it was expected to have a unity correlation (slope =1) passing through the origin. A simple linear regression model without intercepts was used to test the association between primary and secondary cancers for each parameter. For each case, the larger lesion was assigned as the primary lesion. The slopes, coefficient of determinations (R 2 ), Pearson's correlation coefficients (r), and p-values, were obtained by regressing secondary on primary lesions, using SAS statistical packages.
The second test was to compare the differences between regression equations of Group-1 (primary cancer vs. secondary cancer) and Group-2 (primary cancer vs. secondary benign lesion) for each fitting parameter. The analysis of variance of regression coefficients over groups reduction of residuals due to grouping was performed using BMDP New System 2.0 (Statistical Solutions Ltd., 2001). The regression over groups, residual within groups, and the significance F-ratio and p values were obtained, with p < 0.05 considered as significant.
Results
Fitting Quality Using Three Models in Two Case Examples
Figures 1-2 show examples of fitting using three models in one case with two malignant ducal lesions (No. 1). The larger lesion (1.0 cm) was more superficial in the inferior left breast (on slice-20, from a set of 32 slices covering bilateral breasts). The smaller lesion (0.8 cm) was deeper and slightly inferior to the larger lesion (on slice-22). This second lesion was missed in the initial mammography reading, and was subsequently located with MRI finding as guidance. The fitting parameters obtained using 3 different models and the fitting χ2 are summarized in Table I . It can be noted that the wash-out was faster in the smaller lesion and that was reflected in the higher k ep rate in Models-1 and 2, and a higher C in Model-3. Figures 3-4 demonstrate another case (No.
2) with one malignant ductal lesion (on slice-18), and one benign sclerosing adenosis (on slice-12). The enhancement magnitudes were comparable in these two lesions. The benign lesion showed a slower up-slope compared to the cancer, then it reached to a plateau without much wash-out. The parameter v p in Model-1 was lower to account for the slower up-slope. The parameter k ep in Model-2 and the parameter C in Model-3 showed lower rates to account for the slower wash-out. They were the parameters showing the greatest difference between these two lesions in each model.
Association Between Multiple Malignant Lesions in Group-1 Subjects
The enhancement kinetics measured from every lesion was processed in the same way to obtain 8 fitting parameters. Linear regression analysis was performed to investigate the association of fitting parameters obtained from primary and secondary cancers in Group-1 patients. The scattered plot between the parameters measured from the secondary lesion vs. that from the primary lesion using Model-1 analysis are shown in Figure 5 . The results obtained using Model-2 and Model-3 are shown in Figures 6 and 7 , respectively. The linear regression fitting line forcing through the origin is also shown. Since the lesions had the same pathology, if they also had identical MRI kinetics, the data points were supposed to fall on the unity line through the origin. By forcing through origin, the fitting slope indicated the deviation from the unity line (slope =1), and the correlation coefficient further revealed the distribution about the fitting line.
The regression analysis was performed for each parameter, and the obtained slope, coefficient of determination (R 2 ), Pearson's correlation coefficient (r), and the association pvalue are summarized in Table II . For all eight parameters, the slopes are close to 1, and p values < 0.0001, indicating that the primary and secondary cancers are significantly associated with each other, regardless of the analysis model. The parameter v p in Model-1 and the parameter C in Model-3 had slightly worse R 2 compared to others. In some cases the parameters from two lesions were much deviated from the unity line, which was due to their different enhancement kinetics despite of same pathological nature (possibly asso-ciated with different intravascular component or necrosis).
Since the blood kinetics were the same for each patient, the deviation from the unity line gave the range of tumor heterogeneity effects, and that was used to compare to Group-2 cases with benign lesions.
Comparison with Group-2 Subjects with Secondary Benign Lesions
Group-2 had eight patients, each with a primary cancer and a secondary benign lesion. For each parameter, the data are plotted on the same figure (Figs. 5-7) using red symbols, also the p value indicating the significance level in the comparison of differences between these two groups is indicated in each figure. For Model-1 all 3 parameters gave significant differences, p< 0.0001 for k ep , p= 0.002 for v p , and p= 0.007 for K trans . For Model-2, the parameter related to wash-out rate k ep also gave a significant difference (p= 0.0002), whereas the uptake rate K trans failed to differentiate them (p= 0.13). For Model-3, the wash-out parameter C (p= 0.001) and the uptake rate T c (p= 0.005) showed significant differences between Groups-1 and 2, but not the amplitude parameter A (p=0.22). The p values for all eight parameters are summarized in Table III . The results indicated that the wash-out phase (k ep and C) was the most important feature in differentiating benign from malignant lesions, whereas the enhancement magnitude (K trans and A) was comparable between benign and malignant lesions thus could not differentiate them. If analyzed using appropriate models, the early upslope parameter (v p in Model-1 and T c in Model-3) might be able to differentiate between benign and malignant lesions.
Discussion
In this study we compared the enhancement kinetics measured from breast lesions in same patients. The blood kinetics in two lesions would be very similar if not identical, thus the hemodynamic factors were controlled. Furthermore, only malignant lesions which had identical pathological features in the same breast were selected. Therefore, after controlling for the hemodynamic and pathological differences, the comparison of multiple malignant lesions could provide a true account of tumor heterogeneity effect. Group-2 patients had a primary malignant lesion and a benign lesion.
Again the blood kinetics in the benign lesion should be almost the same as that in the malignant lesion. The comparison between Group-1 data (with secondary malignant lesion) and Group-2 data (with secondary benign lesions), all respected to the primary malignant lesion, could control for the hemodynamic factors and truly reveal the differentiation between benign and malignant lesions.
Three different models were used in this study. The standard Tofts model (Model-2, the 2-compartmntal model without vascular component) was initially proposed for studying multiple sclerosis lesions, in which the vascular volume may not be substantial (34). In the last decade, dynamic contrast enhanced study has become a standard for characterization of breast lesions, and the same pharmacokinetic analysis model was applied (29) (30) . Some breast lesions might be highly vascular, and ignoring the vascular component might not be appropriate. However, there were also problems in including a vascular component. When free diffusable tracers such as Magnevist® or Omniscan® were used, it was known that the vascular component was overestimated in the modified . In this study both models, with and without vascular component, were used to analyze the same data sets, and the results could be compared.
In the two cases shown in Figures 1-4 , it was noted that both models yielded satisfactory fitting, but with one more parameter Model-1 could fit the curve better. In Case No. 2 the standard Tofts model (Model-2) overestimated the decay rate, however, it still showed that the decay rate was faster in the malignant lesion (slice-18, Fig. 3 ) than the benign lesion (slice-12, Fig. 4 After confirming that all 3 models could be used to fit the enhancement kinetics satisfactorily, how each parameter revealed the association between primary cancer and secondary cancer was studied next. As shown in Figures 5-7 and Table II , regardless of the analysis model the data obtained from the primary cancer and the secondary cancers showed significant correlation for each parameter, with linear regression slopes close to 1. Therefore, overall there was a significant association between multiple malignant lesions. However, the data points did not fall exactly on the unity line, rather they were distributed within a range, which could be attributed to the different enhancement kinetics measured from the multiple lesions, as well as the choice of models. Many malignant lesions contained intraductal component (or DCIS, ductal carcinoma in situ). The enhancement characteristics of DCIS were different from that of invasive carcinoma, and the extent of DCIS component might affect the measured enhancement kinetics. In addition, there might be some necrotic region contained within the lesion, which could also affect the measured enhancement kinetics. A necrotic center was noted in the primary lesion of Case No. 1 subject (the unenhanced core on the color-coded enhancement map shown in Figure 1(a) ). Although the unenhanced region was excluded in the region of interest, the enhancement kinetics of this lesion had a lower magnitude and a slower wash-out compared to the second lesion shown in Figure 2 , which might be due to presence of necrosis.
After the range of tumor heterogeneity was determined, the Group-1 data was compared to the Group-2 data to determine whether the pharmacokinetic parameter could differentiate the secondary benign lesions from the secondary malignant lesions. All secondary lesions were referenced to the primary cancer to control for the variation from different hemodynamics. The results summarized in Table III indicated that all three parameters in Model-1 (v p , K trans , k ep ) showed significant differences, with p < 0.0001 for k ep . In Model-2 the wash-out parameter k ep also showed a small p=0.0002, but K trans could not separate these two groups. In Model-3, T c and C showed significant differences, but not the amplitude A. When more cases are available, we will be able to compare the sensitivity and specificity of each parameter in making differential diagnosis.
Conclusion
We presented a novel analysis method to investigate the association of multiple malignant lesions (Group-1) in same patients under controlled hemodynamic conditions. To our best knowledge, no such studies were ever published. Overall, the MRI fitting parameters analyzed from the primary cancer and second cancer showed significant correlations. Since the lesions were of identical pathological type, and they were from the same patient, the deviation from the unity line revealed the heterogeneity in MRI enhancement characteristics. The differences might be attributed to different extent of intraductal component or necrosis. Then the results were compared to that from patients with one malignant lesion and a secondary benign lesion (Group-2).
The individual blood hemodynamic difference was controlled by referencing to the primary lesion. The wash-out and the up-slope parameters could significantly differentiate benign from malignant lesions, but not the magnitude parameters. When more data are available it may be possible to establish a reference database, and from which to determine the likelihood of malignancy for each enhancing lesion on MRI. It will be very useful to better characterize the incidental lesions found in preoperative MRI, to prevent unnecessary biopsy or overtreatment. 27.
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